Table 1.
The latest studies that support the association between glyco-oxidation and cardiovascular events or complications in type 2 diabetic patients
| Author (year) | n | Type of study | AGEs | esRAGE | sRAGE | Complication |
|---|---|---|---|---|---|---|
| Kilhovd (2007) | 386 | Longitudinal | ↑ | – | – | Mortality (total, CVD, IHD) in women |
| Lapolla (2007) | 33 | Cross-sectional | ↑ | – | – | PAD |
| Yan (2008) | 151 | Cross-sectional | – | ↓* | ↑ | CAD |
| Lu (2009) | 357 | Cross-sectional | – | ↓ | – | CAD |
| Peng (2009) | 42 | Longitudinal | – | ↘ | – | CAD progression |
| Basta (2011) | 58 | Cross-sectional | – | – | ↑ | IHD |
| Park (2011) | 27 | Cross-sectional | – | ↔ | ↑ | AMI |
| Colhoun (2011) | 167 | Longitudinal | – | ↑ | ↑ | IHD |
| Chen (2011) | 58 | Cross-sectional | ↑ | ↓ | – | PAD |
| Yang (2012) | 41 | Cross-sectional | – | ↔↓ | ↔↓ | Carotid plaque inflammation |
AMI acute myocardial infarction, CAD coronary artery disease, CVD cardiovascular disease, IHD ischemic heart disease, PAD peripheral artery disease, esRAGE endogenous soluble receptor for AGE, sRAGE soluble receptor for AGE
* only esRAGE independently associated with CAD
↘ from baseline in diabetic patients with plaque progression
↔ similar between patients with and without AMI
↔↓ tenderness to be lower (P<0.07) vs healthy controls